Recursion Pharmaceuticals, Inc. (RXRX) vs Supernus Pharmaceuticals, Inc. (SUPN)
A side-by-side comparison of Recursion Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
RXRX
Recursion Pharmaceuticals, Inc.
$4.63HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
SUPN
Supernus Pharmaceuticals, Inc.
$42.83HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — RXRX vs SUPN
growth of $100 · dividends reinvested · last 5yRXRX -73.4% (-23.3%/yr)SUPN +34.2% (+6.1%/yr)SUPN compounded faster over this window
Log scale — wide-divergence pair
RXRX SUPN
RXRX vs SUPN: by the numbers
- •SUPN is the larger company ($2.49B vs $2.43B market cap).
- •Both run net losses; SUPN's is the smaller (-13.23% vs -945.92% net margin).
- •RXRX grew revenue faster over the past five years (45.50% vs 7.78% CAGR).
Metrics side by side
Valuation
| Metric | RXRX | SUPN |
|---|---|---|
| Forward P/E | N/A | 16.70 |
| P/S ratio | 44.29 | 2.99 |
| P/B ratio | 2.65 | 2.41 |
| FCF yield | N/A | 0.76% |
Profitability
| Metric | RXRX | SUPN |
|---|---|---|
| Gross margin | -61.96% | 88.07% |
| Operating margin | -867.87% | -5.13% |
| Net margin | -945.92% | -13.23% |
| ROE | -56.71% | -10.66% |
| ROIC | -49.78% | -10.24% |
Growth (annualized)
| Metric | RXRX | SUPN |
|---|---|---|
| Revenue CAGR (5Y) | 45.50% | 7.78% |
| FCF CAGR (5Y) | N/A | -30.77% |
| Total return CAGR (5Y) | -25.86% | 9.85% |
Frequently asked
- Which has grown faster, RXRX or SUPN?
- Over the past five years, RXRX grew revenue faster — RXRX at a 45.50% CAGR versus SUPN at 7.78%.
- How have RXRX and SUPN total returns compared?
- Over the past 5 years, RXRX delivered -25.86% and SUPN delivered 9.85% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Recursion Pharmaceuticals ROESupernus Pharmaceuticals ROERecursion Pharmaceuticals operating marginSupernus Pharmaceuticals operating marginRecursion Pharmaceuticals revenue growthSupernus Pharmaceuticals revenue growthRecursion Pharmaceuticals free cash flowSupernus Pharmaceuticals free cash flow
Recursion Pharmaceuticals & Supernus Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.